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Abstract
Background:  Declining levels of surfactant protein A (SP-A) after lung transplantation are
suggested to indicate progression of ischemia/reperfusion (IR) injury. We hypothesized that the
previously described preservation-dependent improvement of alveolar surfactant integrity after IR
was associated with alterations in intraalveolar SP-A levels.
Methods:  Using immuno electron microscopy and design-based stereology, amount and
distribution of SP-A, and of intracellular surfactant phospholipids (lamellar bodies) as well as
infiltration by polymorphonuclear leukocytes (PMNs) and alveolar macrophages were evaluated in
rat lungs after IR and preservation with EuroCollins or Celsior.
Results: After IR, labelling of tubular myelin for intraalveolar SP-A was significantly increased. In
lungs preserved with EuroCollins, the total amount of intracellular surfactant phospholipid was
reduced, and infiltration by PMNs and alveolar macrophages was significantly increased. With
Celsior no changes in infiltration or intracellular surfactant phospholipid amount occurred. Here,
an increase in the number of lamellar bodies per cell was associated with a shift towards smaller
lamellar bodies. This accounts for preservation-dependent changes in the balance between
surfactant phospholipid secretion and synthesis as well as in inflammatory cell infiltration.
Conclusion: We suggest that enhanced release of surfactant phospholipids and SP-A represents
an early protective response that compensates in part for the inactivation of intraalveolar surfactant
in the early phase of IR injury. This beneficial effect can be supported by adequate lung preservation,
as e.g. with Celsior, maintaining surfactant integrity and reducing inflammation, either directly (via
antioxidants) or indirectly (via improved surfactant integrity).
Background
Surfactant protein A (SP-A) is the major surfactant-associ-
ated protein, and is of central importance to the structure,
metabolism, and function of pulmonary surfactant (as
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reviewed by [1-3]). It is also important for the regulation
of inflammatory processes and for innate host defence of
the lung (as reviewed by [4]).
Reduced intraalveolar levels of SP-A were found to be
associated with several pulmonary diseases [5,6]. In the
pathological situation, SP-A is therefore suggested to be
an important regulator of surfactant function. In lung
transplant recipients, impairment of pulmonary sur-
factant activity was associated with an increased ratio of
small-to-large surfactant aggregates and a reduced content
of SP-A [7,8]. Using an extracorporeal model of ischemia/
reperfusion (IR) injury in the rat lung, we showed preser-
vation-dependent alterations in the ratio between inactive
(unilamellar vesicles) and active (tubular myelin) sur-
factant components [9]. Based on these studies, we
hypothesize preservation-dependent effects on the
amount and distribution of intraalveolar SP-A. We further
propose that the preservation-dependent differences in
the amount of surface active surfactant in the alveoli are
associated with alterations of the intracellular surfactant
pool.
An established extracorporeal rat lung model was used to
study the cumulative effects induced by the whole
sequence of transplantation-related events, which
includes flush perfusion, cold ischemic storage, and sub-
sequent reperfusion of the lung, rather than looking at the
relative contribution of the individual events. The quality
of preservation by the solutions, EuroCollins and Celsior,
was compared using established stereological methods
[10,11]. These design-based techniques allow for a quan-
titative structural analysis in the organ by light and elec-
tron microscopy. The methods are unbiased, efficient, and
representative for the whole lung (for review see [12]).
Methods
Animals
Twenty-four male Sprague-Dawley rats (Crl:CD; Charles
River, Sulzfeld, Germany) received pentobarbital intra-
peritoneally (Nembutal 1 mg/kg body weight), were intu-
bated by tracheostomy, and heparinized via the vena cava
inferior. Animal experiments were performed according
to the Helsinki convention for the use and care of animals.
The experiments have been approved by the regional
government.
Study design
The study was particularly designed to investigate if Euro-
Collins and Celsior solution were able to adequately pre-
serve the levels of surfactant protein A (SP-A) and of the
intracellular surfactant phospholipid stores. In order to
consider a preservation solution as adequate, it should be
effective throughout the periods of ischemia and reper-
fusion in maintaining levels, which are characteristic for a
native lung. Therefore, two separate sets of experiments
were performed: 1) preparation for SP-A analysis by
immuno electron microscopy (n = 3 per group) and 2)
preparation for surfactant phospholipid analysis by con-
ventional transmission electron microscopy (n = 5 per
group). Each experimental set comprised three groups: 1)
controls: no intervention (native lungs), 2) EuroCollins:
flush perfusion with Euro Collins solution containing 40
mMol potassium (EC40) supplemented with 6 µg/100 ml
prostacyclin (Epoprostenol; Flolan, Wellcome, Becken-
ham, UK), and 3) Celsior: flush perfusion with Celsior
(IMTIX, Pasteur Merieux, France); both 2) and 3) with 120
minutes of ischemia (at 10°C), and 50 minutes of
reperfusion.
Extracorporeal model of ischemia/reperfusion injury
Operation and excision of the heart-lung-block was per-
formed as described recently [13]. Lungs were flushed via
the pulmonary artery at a hydrostatic pressure of 20 cm
H2O with preservation solution (for composition, see
Table 1). Ischemic storage (120 min) was followed by a
50-min reperfusion via the pulmonary artery with Krebs-
Henseleit-buffer (8.0 ml/min at 37°C) containing bovine
red blood cells (hematocrit of 38 to 40%) using a quattro
head roller pump (Mod-Reglo-Digital, Ismatec, Zürich,
Switzerland).
Lung function measurements
Perfusate oxygenation (∆PO2), peak inspiratory pressure
(PIP) as well as pulmonary arterial pressure (PAP) were
measured at the end of the reperfusion period of 50 min-
utes as described earlier [9].
Table 1: Composition of Preservation solutions
Components EuroCollins [mmol/l] Celsior® [mmol/l]
Na+ 85 100
K+ 40 15
Mg2+ -1 3
Ca2+ - 0.26
Cl- 15 41.5
PO4
2- 57.5 -
HCO3- 10 -
Histidine - 30
Mannitol - 60
Glucose 3.5 [%] -
Glutamate - 20
Lactobionate - 80
Glutathione - 3
osmolarity 370 360Respiratory Research 2005, 6:60 http://respiratory-research.com/content/6/1/60
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Fixation, tissue sampling and processing
Fixation by vascular perfusion and tissue sampling as well
as tissue processing for standard and immuno electron
microscopy have been described previously [9,14,15].
Lung volume was determined and isotropic uniform ran-
dom samples (IUR) of lung tissue were taken and proc-
essed according to standard methods [14]. The tissue
samples were embedded either in glycolmethacrylate
resin (Technovit 7100, Heraeus, Kulzer, Germany) for
light microscopy, or in Araldite for electron microscopy.
For immuno electron microscopy, lungs were fixed with
4% paraformaldehyde/ 0.1% glutardialdehyde in 0.2 M
Hepes buffer. After collection of IUR tissue samples (see
above), 2 mm3 tissue blocks were infiltrated in 2.3 M
sucrose in PBS for at least 1 hour and frozen in liquid
nitrogen, then freeze-substituted (Reichert AFS; Leica,
Vienna, Austria) in 0.5% uranyl acetate in methanol at -
90°C for at least 36 hours and embedded in Lowicryl
HM20 (Polysciences, Eppelheim, Germany) at -45°C (for
details see [14]).
Immunolabelling
Ultrathin sections (70 nm thickness) were labelled with
affinity purified polyclonal primary antibody against SP-A
(dilution 1:40 for labelling of type II pneumocytes and
1:150 for labelling of tubular myelin; kind gift from Dr. S.
Hawgood, San Francisco) and gold-coupled secondary
antibody (dilution 1:20; British Biocell; Cardiff, UK) with
a gold particle diameter of 10 nm for detection. Control
experiments were performed by omission of the primary
antibody. Immunolabelling was examined using an EM
900 (LEO, Oberkochen, Germany) at a magnification of ×
20,000.
Stereological analysis of SP-A labelling
The numbers of gold labelling on tubular myelin as well
as on nucleus, mitochondria, lamellar bodies and the
remaining cytoplasm (including vesicles) of type II pneu-
mocytes were counted and related to the volume fraction
of the cellular compartments and to the length of tubular
myelin phospholipid layers as described by Griffiths [16].
The relative labelling index (RLI), was determined to test
for preferential labelling of different cell compartments
according to a recently described method, which allows
for clearer distinction between specific labelling and
unspecific background staining [15,17]. A total of 172
profiles of alveolar epithelial type II cells were analyzed.
The total number of gold particles counted over alveolar
epithelial type II cell profiles was 10,530, thus the mean
number of gold particles counted per cell profile was 61.
Using intersection counting, labelling density of SP-A over
the tubular myelin lattices was determined as particle
number referred to the length of the profile of the phos-
pholipid layers forming the lattice according to the for-
mula: Ngold / length = Ngold  / I × d with number of
intersections (I) and distance between the test lines (d).
Using point counting, the labelling density of SP-A over
type II cell profiles was determined according to the for-
mula: Ngold = Ngold / p × d2 with number of points (p) and
distance between the test lines (d). Due to the dependence
of the effective resolution of gold labelling on the size of
the underlying particles [16], we did not choose to sepa-
rate the vesicles from the cytoplasmic compartment to
avoid uncertainties and misinterpretations in the alloca-
tion of the gold particles.
Stereological analysis of alveolar epithelial type II cell 
parameters and lamellar bodies
Number and volume of alveolar epithelial type II cells
(AEC II) as well as number, size, and volume of lamellar
bodies were quantified on a computer-assisted light
microscope (Cast-Grid 2.0, Olympus, Denmark) using
the physical disector, rotator, and point-sampled inter-
cepts method as previously described in detail [11]. AEC
II (93 ± 9SEM per lung) were sampled by light microscopy
on glycolmethacrylate sections using the single section
disector [12].
According to Ochs and co-workers [10], the physical dis-
ector was used for counting the number of lamellar bodies
and of type II pneumocytes, which allows for quantifica-
tion of the intracellular pool of surfactant phospholipids
per cell and per unit lung volume. Disector counting of
lamellar bodies was performed on sets of two parallel
ultrathin sections with a known separation of approxi-
mately 100 nm (estimated by the Small fold method
according to [18]), the reference and the look-up or sam-
pling section (Fig. 1).
The apical (secretory) fraction of the AEC II surface (SS)
and the mean volume-weighted particle volume ( ) of
lamellar bodies was determined on electron micrographs
(magnification ×7500) of AEC II, which had been sam-
pled in a systematic uniform random manner, by means
of the point-sampled intercept method [11] (Fig. 2). The
number-weighed mean volume (VNLb) of lamellar bodies
was calculated by dividing the total volume of lamellar
bodies (VLb per cell by the total number (NLb) of lamellar
bodies per cell.
Stereological analysis of polymorphonuclear leukocytes 
(PMN) and alveolar macrophages
The volume densities and total volume of PMNs and alve-
olar macrophages in lung parenchyma was evaluated by
point counting according to standard methods [14] using
computer-assisted light microscopy (Cast-Grid 2.0, Olym-
pus, Denmark).
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Statistics
Differences between the experimental groups and the con-
trol group were tested for significance with parametric
One Way ANOVA followed by post hoc multiple compar-
isons (Dunnett's method) provided that normality and
equal variance given at p>0.1 were given. The differences
in the size classes of lamellar bodies were tested by Mann-
Whitney-U test. Otherwise, non-parametric Mann-Whit-
ney rank sum test or Kruskal-Wallis One Way ANOVA on
ranks was used. Mean values are given ± SEM unless
otherwise indicated. Preferential or specific labelling for
SP-A was tested by χ2-analysis [17]. Correlations between
stereological and lung function parameters were tested by
multivariate analysis using forward stepwise regression to
identify those stereological parameters that were predic-
tors of ∆PO2, PIP, and PAP, respectively. All statistical
analyses and graphic presentations were performed using
the SigmaStat2.0 and SigmaPlot8.0 software programs
(Jandel Scientific, Erkrath, Germany). p values < 0.05 were
considered to be significant unless otherwise indicated.
Results
Surfactant protein A
Labelling for SP-A was strongest over the lattice structures
of tubular myelin figures in all study groups and was sig-
nificantly increased in lungs after ischemia and reper-
fusion (IR) (Table 2; Fig. 3). Characteristic alterations of
the tubular myelin ultrastructure, e.g. enlargement of the
side dimensions of the tubular myelin lattices, termed as
mesh width, appearance of unilamellar vesicles among
disintegrating lattices, and dislocation of tubular myelin
from the alveolar wall could either be accompanied by
Principle of Physical Disector Figure 1
Principle of Physical Disector. Electron micrographs showing sets of two parallel sections (~100 nm thick) of an alveolar 
epithelial type II cell. Three lamellar bodies (arrowheads), which only occur in the sampling section, were counted as well as 
one lamellar body (arrow) seen in the reference section, because the principle of bidirectional counting was applied. Nucleus 
(N), nucleolus (Nu), lamellar body (Lb), capillary (Ca).
Logarithmic Ruler Figure 2
Logarithmic Ruler. Logarithmic ruler and formula for the 
determination of the volume weighted mean volume ( ) of 
lamellar bodies according to Brændgaard and Gundersen 
[37].
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weak or by strong labelling for SP-A without any
preferential association (Fig. 4). Densely clustered intraal-
veolar lamellar body-like forms showed SP-A labelling
over peripheral lamellae, whereas unclustered forms as
well as unilamellar vesicles did not display any labelling
for SP-A (Fig. 5A).
Within alveolar epithelial type II cells, SP-A was localized
mainly in small vesicles and multivesicular bodies close to
the lamellar bodies (Fig. 5B, C). Labelling of lamellar bod-
ies was rare and was usually associated with an electron
dense area (Fig. 5C). Estimation of the relative labelling
index (RLI) revealed a highly significant (p < 0.001) non-
random labelling for the cytoplasm in all three groups
(see Additional File 1). Cytoplasmic labelling for SP-A was
below control value after IR, but differences between the
groups achieved a level of significance of 0.05 < p < 0.1
only (Table 2).
Surfactant phospholipid structures
In lungs that had been preserved with EuroCollins, the
side dimensions of the tubular myelin lattices (mesh
width) were significantly increased compared to control
lungs. After preservation with Celsior, changes in the lat-
tice microstructure were quite variable and, in contrast to
previous data [9], the tubular myelin mesh width did not
show any significant alteration compared to the other
groups (Table 2; Fig. 4B).
The total volume of lamellar bodies (VLb) per lung was sig-
nificantly decreased in lungs preserved with EuroCollins
solution as compared with the control group (Table 3).
This was accompanied by a decrease in the volume of
lamellar bodies (VLb) per type II cell, which, however, was
not statistically significant (Table 3; Fig. 6C). There was no
difference in the amount of intracellular surfactant (per
lung as well as per cell) between the Celsior and the con-
trol groups (Table 3; Fig. 6A, B). In lungs preserved with
Celsior, there was a significant reduction in the number-
weighted mean volume ( ) of lamellar bodies in
comparison to the control group (Table 3). This was
accompanied by a significant increase in the fraction of
small section profiles of lamellar bodies after IR compared
to controls (Fig. 7).
Table 2: Characteristics of Tubular Myelin Ultrastructure and Labelling Density of Surfactant Protein A (SP-A)
Parameter Control EuroCollins Celsior
Mesh width of tubular myelin [nm] 30.6 ± 3.3 43.8 ± 1.3* 32.7 ± 4.0
Number of gold particles (SP-A) on tubular myelin1 [µm-1] 11.1 ± 1.5 31.9 ± 3.5* 35.9 ± 0.2*
Number of gold particles (SP-A) on AEC II cytoplasm2 [µm-2] 4.2 ± 0.4 3.1 ± 0.3# 2.9 ± 0.2#
means ± SEM of n = 3 per group; *p < 0.05 and #0.05 < p < 0.1 versus control
1 gold particle counts are referred to the length of the phospholipid layer cross sections composing the tubular myelin lattices
2 gold particle counts are referred to the sectioned area of AEC II
Intact tubular myelin immunolabelled for SP-A Figure 3
Intact tubular myelin immunolabelled for SP-A. Immunolabelling for SP-A on ultrastructurally intact tubular myelin 
(TM) lattices A) in the control, B) after ischemia and reperfusion following preservation with either Celsior or C) EuroCollins. 
Alveolar lumen (AL), epithelium (EPI).
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Altered tubular myelin immunolabelled for SP-A Figure 4
Altered tubular myelin immunolabelled for SP-A. Immunolabelling for SP-A on altered tubular myelin (TM) lattices: A) 
tubular myelin is dislocated from the alveolar wall in a control lung and B) after ischemia and reperfusion following preservation 
with Celsior; C) and D) side dimensions of the tubular myelin lattices is enlarged after ischemia and reperfusion following pres-
ervation with either Celsior (C) or EuroCollins (D). Alveolar lumen (AL), basal lamina (BL), capillary (CA), edema (ED), epithe-
lium (EPI).Respiratory Research 2005, 6:60 http://respiratory-research.com/content/6/1/60
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Alveolar epithelial type II cells
Type II cells as well as their subcellular compartments dis-
played significant oedematous swelling in lungs after IR as
indicated by markedly increased volumes of the cells,
cytoplasm, nuclei, and mitochondria compared to the
controls (Table 4; Fig. 6). The surface fraction of the apical
secretory surface of type II pneumocytes was unchanged
after IR (Table 4).
Polymorphonuclear leukocytes (PMN) and alveolar 
macrophages
Total volumes as well as volume densities of PMN (resid-
ing in the capillary bed) and alveolar macrophages (in the
alveolar space) in the gas-exchange region were signifi-
cantly increased (p < 0.05) after preservation with Euro-
Collins as compared with control lungs (Table 5). In lungs
preserved with Celsior, PMN volume was similar to con-
trol lungs.
Structure-function correlations
The quantitative-morphological parameters given in
Tables 3, 4 and 5 were tested for potential correlation with
the lung function parameters recorded at the end of the
reperfusion period, i.e. immediately prior to fixation
(Table 6). Multivariate regression analysis revealed that
PIP can be predicted from a linear combination of the
total volume of alveolar macrophages (r2 = 0.514; p =
0.005) and the number of lamellar bodies (r2 = 0.843; ∆r2
= 0.329; p = 0.006). ∆PO2 can be predicted from a linear
combination of the total alveolar macrophage volume (r2
= 0.536; p < 0.001) and total lamellar body volume (r2 =
0.862; ∆r2 = 0.326; p = 0.005). There were no correlations
Surfactant subtypes immunolabelled for SP-A Figure 5
Surfactant subtypes immunolabelled for SP-A. Specific labelling for SP-A did not occur on A) unclustered lamellar body-
like surfactant forms (LBL) nor unilamellar vesicles (ULV); B) cytoplasm/multivesicular bodies (arrows) displayed specific label-
ling for SP-A (RLI  1.57) whereas C) the weak labelling of intracellular lamellar bodies (LB) was non-specific (RLI  0.34). 
Tubular myelin (TM).
Table 3: Characteristics of lamellar bodies (Lb)
Parameter Control EuroCollins Celsior
Number (NLb) / AEC II 92.9 ± 5.4 97.9 ± 13.2 121.2 ± 10.0
Volume (VLb) / AEC II [µm3] 58.2 ± 2.4 50.1 ± 3.2 57.4 ± 5.1
Total Volume (VLb) per lung [109 µm3] 9.0 ± 0.9 5.4 ± 0.6* 6.3 ± 0.8
Mean Volumenumber-weighted ()  [ µm3]
0.63 ± 0.06 0.55 ± 0.18 0.48 ± 0.10*
means ± SEM of n = 5 per group; *p < 0.05 versus control
VNLbRespiratory Research 2005, 6:60 http://respiratory-research.com/content/6/1/60
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between lung function parameters and PMNs or other
AECII related parameters.
Discussion
We hypothesized that the previously described preserva-
tion-dependent improvement of alveolar surfactant integ-
rity after ischemia and reperfusion (IR) [9] was associated
with changes in the amount and distribution of SP-A as
well as with alterations in the intracellular surfactant pool
of alveolar epithelial type II cells. Using immuno electron
microscopy, we showed that the labelling density of tubu-
lar myelin-associated SP-A was significantly enhanced
after IR, and that the previously reported increase of the
intraalveolar surfactant phospholipids [9] was paralleled
by a trend to decreased intracellular SP-A levels. The total
volume of intracellular surfactant phospholipids was sig-
nificantly decreased in lungs perfused with EuroCollins,
whereas lungs preserved with Celsior did not significantly
differ from control lungs. The maintenance of intracellu-
lar surfactant in Celsior preserved lungs was achieved by
an increase in the lamellar body number per alveolar epi-
thelial type II cells despite a significant decrease in the
number-weighted mean volume of lamellar bodies,
which is indicative of an increased level of surfactant
phospholipid formation. The improved preservation of
the surfactant system by Celsior was accompanied by an
anti-inflammatory effect, which was reflected by normal
levels of polymorphonuclear leukocytes and alveolar
macrophages. Improved lung function achieved by Cel-
sior, as compared with EuroCollins, resulted from both
enhanced preservation of the intracellular surfactant sys-
tem and an anti-inflammatory effect.
In this study, we showed that the total amount of intrac-
ellular surfactant, determined by a novel unbiased stereo-
logical approach [10,11], remained unchanged in lungs
preserved with Celsior when compared to control lungs,
whereas it was decreased after preservation with EuroCol-
lins. Young and co-workers [19] demonstrated a correla-
tion between biochemical and morphometric parameters
in the quantification of intracellular surfactant, i.e. lamel-
lar bodies, so that we can assume that the amount of
lamellar bodies corresponded to the biochemical sur-
factant phospholipid pool in the cells. Since the apical
surface fraction of type II cells was unchanged after IR, it
can be assumed that exocytosis and endocytosis of sur-
factant were well balanced. In contrast, the apical cell sur-
face is expected to grow when more surfactant is secreted
than recycled, which is based on the finding that the
lamellar body membrane is incorporated into the cell sur-
face during exocytosis [20]. Thus, the reduced amount of
intracellular surfactant in lungs preserved with EuroCol-
lins, is suggested to reflect a decrease in surfactant synthe-
sis rather than an increase in surfactant secretion. After
preservation with Celsior, the size reduction of lamellar
bodies was compensated by a greater number, in a way
that the total amount of intracellular surfactant stayed in
Ultrastructural appearance of alveolar epithelial type II cells Figure 6
Ultrastructural appearance of alveolar epithelial type II cells. Alveolar epithelial type II cells differ in cell size as well as 
size and amount of lamellar bodies (LB) in A) the control and B) after ischemia and reperfusion following preservation with 
either Celsior or C) EuroCollins. Nuclei (N) and mitochondria (M) display edematous swelling in the treatment groups. Alveo-
lar lumen (AL), capillary (CA).Respiratory Research 2005, 6:60 http://respiratory-research.com/content/6/1/60
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Histogram of lamellar body size classes Figure 7
Histogram of lamellar body size classes. Distribution of lamellar body size classes (increasing from 1 to 15) after ischemia 
and reperfusion (IR) following preservation with either Celsior or EuroCollins compared to control lungs as determined by the 
point sampled intercepts method. After IR, lamellar bodies of size class1 (smallest size) differ significantly from controls (Cel-
sior: p = 0.032; EuroCollins: p = 0.028). Bars represent means ± SD.
Table 4: Characteristics of Type II Alveolar epithelial cells (AEC II)
Parameter Control EuroCollins Celsior
Apical surface fraction
(SSapical surface per total AEC II 
surface) [%]
47.8 ± 1.9 47.1 ± 1.4 47.3 ± 1.2
Volumes [µm3]
Total Cell (VAECII) 322.5 ± 9.6 485.4 ± 33.7* 496.2 ± 37.4*
Cytoplasm (VCyt) AECII 178.0 ± 5.1 279.6 ± 16.3* 279.2 ± 24.3*
Nucleus (VNu) / AEC II 65.0 ± 3.9 117.5 ± 15.6* 125.0 ± 9.3*
Mitochondria (VMito) / AEC II 21.4 ± 1.4 38.2 ± 4.6* 34.6 ± 2.2*
means ± SEM of n = 5 per group; *p < 0.05 versus control
size classes of lamellar bodies
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the range of native lung values. This suggests that
surfactant synthesis by type II pneumocytes was increased
in the Celsior group.
Immunolabelling for SP-A was highly specific showing
quite intensive labelling of the tubular myelin. Unlike
some other studies [15,21,22], no specific labelling of
unilamellar vesicles or lamellar body-like forms could be
detected, though occasional labelling occurred. Biochem-
ical analysis revealed that SP-A accounts for about 1% of
total lamellar body protein [23,24] and about 4 to 8% of
total lung SP-A was suggested to be present in lamellar
bodies [23,25]. However, in the rat, lamellar bodies are
less well preserved during cryosubstitution procedures
than e.g. in human lung tissue [15], which may account
for the low labelling density of lamellar bodies for SP-A in
the present study.
The increased labelling density of tubular myelin for SP-A
after IR was paralleled by an increase in the total amount
of tubular myelin, which was highest after preservation
with Celsior [9]. Based on the increase in both, SP-A label-
ling density as well as tubular myelin volume, the total
amount of intraalveolar SP-A can be inferred to be
enhanced after IR in the Celsior group. SP-A levels were
found to be unchanged [26] or even reduced [26,27] in
the bronchoalveolar lavage fluid (BALF) from canine
lungs after IR. These differences were shown to depend on
the duration of ischemia. Without any specific lung pres-
ervation, endogenous SP-A as well as intraalveolar sur-
factant phospholipids dropped significantly in the BALF
from rat lungs after 20 hours of cold ischemia and further
decreased markedly after 1 hour of reperfusion [28]. Inter-
estingly, the drop in endogenous SP-A could be reversed
by instillation of SP-A-enriched as well as SP-A-deficient
surfactant [28]. Thus, high intraalveolar phospholipid lev-
els, as were quantified in our model [9], could be a trigger
to stimulate the release of endogenous SP-A. This may rep-
resent an early protective response that compensates in
part for the IR related surfactant inactivation. This protec-
tive potential of the lung appears to vanish with extended
time of ischemia [26,27], and in the clinical transplant sit-
uation [5,7,8] where the declining release of surfactant
phospholipids and SP-A may result from yet suboptimal
preservation procedures.
Notably, Celsior preserved lungs had almost normal
amounts of polymorphonuclear leukocytes and alveolar
macrophages, whereas both cell populations were signifi-
cantly increased in lungs preserved with EuroCollins.
Both cell types are well known to release reactive oxygen
species (ROS) [29]. ROS, which are formed during early
reperfusion, are suggested to inactivate surfactant phos-
pholipids [30]. Additionally, nitration of SP-A was shown
to affect its ability to aggregate lipids [31], and oxygen
exposure was shown to increase surfactant protein expres-
sion [32]. High levels of SP-A were shown to counteract
the inhibition of surfactant by serum proteins [33], and to
restore the activity of oxidized surfactant in vitro [34]. The
high protective potential of the Celsior solution has been
attributed to the presence of antioxidants such as glutath-
ione and lactobionate, which are thought to counteract
Table 5: Characteristics of polymorphonuclear leukocytes and alveolar macrophages in lung parenchyma
Parameter Control EuroCollins Celsior
Total Volume [mm3]
PMNs 1.7 ± 0.40 14.3 ± 10.0* 2.2 ± 0.6
Macrophages < 0.01 6.3 ± 1.6* 1.2 ± 0.2
Volume density [mm3/mm3]
PMNs 0.03 ± 0.01 0.36 ± 0.25* 0.05 ± 0.01
Macrophages < 0.01 0.15 ± 0.03* 0.03 ± 0.01
means ± SEM of n = 5 per group; *p < 0.05 versus control
Table 6: Lung function characteristics after 50 min of reperfusion
Parameter EuroCollins Celsior
Perfusate ∆PO2 [mm Hg] 38.5 ± 8.2 126.0 ± 14.5**
Peak inspiratory pressure [cm H2O] 15.3 ± 2.2 11.2 ± 1.0
Pulmonary arterial pressure [cm H2O] 10.7 ± 1.2 9.4 ± 0.7
means ± SEM of n = 5 per group; ** p < 0.001 versus EuroCollinsRespiratory Research 2005, 6:60 http://respiratory-research.com/content/6/1/60
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the formation of ROS during IR [35]. As multivariate anal-
ysis indicates that both low mass of alveolar macrophages
and high amount of intracellular surfactant are predictors
for lung function parameters, it appears likely that Celsior
exerts a dual effect on both infiltrating immune cells and
integrity of the surfactant system. Whether the anti-
inflammatory effect of Celsior is an indirect result of the
improved preservation of the surfactant system, the inac-
tivation of which contributes to an enhanced susceptibil-
ity of the lung to inflammation [36], or whether it is a
direct effect of its antioxidant components remains to be
elucidated.
Conclusion
In summary, preservation with Celsior increased intraal-
veolar SP-A levels, stabilized the amount of intracellular
surfactant and reduced lung inflammation. In contrast,
significant changes of the tubular myelin microstructure
and reduction in the amount of intracellular surfactant as
well as increased inflammatory cell infiltration occurred
in lungs that had been preserved with EuroCollins. We
suggest that high intraalveolar levels of surfactant phos-
pholipid and SP-A represent an early protective response
directed to compensate for the inactivation of intraalveo-
lar surfactant in the early phase of IR injury. We further
suggest that maintenance of alveolar epithelial type II cell
function by improved lung preservation will support this
inherent protective response during early reperfusion.
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